B. Riley Comments on biote’s Q2 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD) – Equities researchers at B. Riley lowered their Q2 2025 earnings estimates for shares of biote in a report issued on Friday, May 9th. B. Riley analyst J. Van. Sinderen now forecasts that the company will post earnings per share of $0.03 for the quarter, down from their previous forecast of $0.05. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s FY2027 earnings at $0.72 EPS.

Separately, Craig Hallum lowered their target price on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

biote Trading Down 2.0%

biote stock opened at $3.91 on Monday. The stock has a market cap of $213.92 million, a price-to-earnings ratio of 15.04 and a beta of 1.17. The company’s 50-day moving average price is $3.60 and its two-hundred day moving average price is $4.92. biote has a 52 week low of $3.04 and a 52 week high of $8.44.

biote (NASDAQ:BTMD) last released its earnings results on Wednesday, May 7th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. The firm had revenue of $48.99 million for the quarter, compared to analysts’ expectations of $47.25 million. biote had a net margin of 5.20% and a negative return on equity of 32.41%.

Insider Transactions at biote

In other biote news, major shareholder Guines Llc acquired 106,000 shares of the stock in a transaction dated Monday, March 31st. The shares were bought at an average price of $3.32 per share, with a total value of $351,920.00. Following the purchase, the insider now directly owns 4,033,547 shares of the company’s stock, valued at approximately $13,391,376.04. This trade represents a 2.70% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Stephen Mark Cone acquired 38,104 shares of the stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $3.88 per share, for a total transaction of $147,843.52. Following the purchase, the director now directly owns 160,829 shares in the company, valued at approximately $624,016.52. The trade was a 31.05% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 1,412,080 shares of company stock valued at $4,598,190 in the last quarter. Insiders own 24.00% of the company’s stock.

Hedge Funds Weigh In On biote

Several hedge funds have recently made changes to their positions in the business. Kanen Wealth Management LLC purchased a new position in shares of biote in the fourth quarter worth approximately $1,791,000. Nuveen LLC purchased a new position in shares of biote in the first quarter worth approximately $872,000. Hillsdale Investment Management Inc. purchased a new position in shares of biote in the fourth quarter worth approximately $1,561,000. Marshall Wace LLP purchased a new position in shares of biote in the fourth quarter worth approximately $543,000. Finally, Trexquant Investment LP increased its position in shares of biote by 423.1% in the fourth quarter. Trexquant Investment LP now owns 101,757 shares of the company’s stock worth $629,000 after acquiring an additional 82,303 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.